Effect of Growth Hormone in Metabolic Syndrome

• Status: Unknown status
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: Male

Summary

Investigating the effect of low dose growth hormone therapy on body fat composition, insulin sensitivity and metabolic profiles in middle-aged men with metabolic syndrome and low insulin-like growth factor (IGF-1) level.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese University of Hong Kong
• Treatments: Hormones

Criteria

Inclusion Criteria:

• Age 35 to 50 Chinese men

• Metabolic syndrome as defined according to 1998 World Health Organisation with modification using Asian definition for obesity (body mass index 25kg/m2, waist circumference 80cm in women and 90 cm in men)

• Low IGF-1 level or IGF-1 level in low normal range (<200 ug/L)

Exclusion Criteria:

• Any malignancy within the past 5 years

• A diagnosis of acromegaly

• Uncontrolled hypertension (systolic blood pressure >180mmHg or diastolic blood pressure>105mmHg)

• A history of carpel tunnel syndrome

• Poor glycemic control (HbA1c>8%)

• Diabetic microangiopathy

• Previous cardiovascular event

• Anaemia as defined as haemoglobin <11g/dL

• Active thyroid diseases

• Any medical illness that will render the subject vulnerable to fluid retention state, e.g. renal impairment, heart failure or as judged by the investigators as ineligible to participate the study.